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A PATIENT’S JOURNEY
Superficial spreading melanoma
This patient was diagnosed with superficial spreading melanoma, which had spread to the lymph
nodes. Treatment seems to have been successful, but she has been perturbed by some clinicians’
reluctance to discuss prognosis
Penny D’Ath patient 1, Penny Thomson associate specialist in dermatology 2
1Department of Optometry and Visual Science, City University London, London EC1V 0HB, UK; 2Barnet and Chase Farm Hospitals NHS Trust,
Barnet Hospital, Barnet EN5 3DJ (penny.thomson@.nhs.net)
This is one of a series of occasional articles by patients about their
experiences that offer lessons to doctors. The BMJ welcomes
contributions to the series. Please contact Peter Lapsley
(plapsley@bmj.com) for guidance.
“You do understand this is cancer?” asked the dermatologist.
It would be another few months before I fully understood the
significance of this sentence and its implications. At that precise
moment, it was just a mole: asymmetric, with irregular borders,
of different colours, bigger than the diameter of a pencil, and
elevated. In fact, everything the ABC rules of dermatology said
it shouldn’t be. My GP had said it would probably be fine, and
I could leave it alone. Only it hadn’t been fine, and it was lucky
I hadn’t left it alone. Except that it had been left alone long
enough to march unrepentantly to my lymphatics, where it had
settled comfortably into my sentinel node.
The dermatologist had just confirmed Google’s tentative
diagnosis of a superficial spreading melanoma. She mentioned
survival rates. What? Along with the rest of the population, I
thought that if it was malignant they would cut it out and that
would be the end of it. Survival rate? This was a new concept,
and one that I hadn’t entertained.
My mole had a low mitotic rate (good), minimal inflammation
(good), and no ulceration (good). On the other hand, it had a
Breslow thickness of 1.8 mm and was Clark level IV, meaning
that it was neither early nor thin. It was a mole with a mission.
I found it incredible that something so thin—1.8 mm for
goodness sake—could kill.
I returned one week after the wide excision and sentinel node
biopsy to receive my results. The odds were heavily in my
favour, as 80% of patients have no sentinel node involvement.
The surgeon rather overplayed the fact that the wide excision
was clear, and I could tell by his eager delivery of this result
that the next one would be less favourable. I was right; the
sentinel node was positive.
I returned for axillary clearance. The “likely” side effect of
lymphoedema frightens me more than anything else. Not only
cosmetically (who wants to look like the Michelin man?) but
also functionally (I am very right hand dominant).
The results were good: 15 nodes removed, none cancerous, stage
IIIa regional metastasis. My upper arm and shoulder are numb,
but this is a small price to pay. I was elated. I opened a bottle
of champagne and got drunk. Then came the questions.
The plastic surgeon told me that the survival rate for people
with my condition was above 90%. This couldn’t be right. I had
understood that it had been above 90% before they knew the
cancer had marched triumphantly to the sentinel node and
planted its flag. Thankfully, it hadn’t started its ascent towards
the summit, but was firmly ensconced in base camp at two
separate locations.
The dermatologist told me survival was 67% at five years. One
in three people would be dead in five years? “If that’s the way
you want to look at it,” she said with exasperation in her voice,
which rather suggested she wished I hadn’t vocalised this. It
wasn’t that I wanted to see it that way; rather I couldn’t really
believe I might be staring my mortality in the face at the age of
41. I don’t really believe I will die, because I am only 41 and
it’s only a mole. Also, I know the dermatologist won’t let me
die—even though, deep down, I understand that if the scud
missile has me on its radar, there is nothing she can do. She
explained that they knew there was no cancer where the mole
had been (hence the wide excision) nor in the lymph nodes
(hence the axillary clearance). What no one knew was whether
there were any micrometastases in transit between the mole site
and the lymph nodes. This was the piece of information that I
lacked.
Perhaps I should have mentioned earlier that I am a
“complicated” patient as there are various possibilities as to
why I had this melanoma. The commonest cause is sun exposure,
but I am definitely not an ardent sun worshipper. It is more
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probably because of the biologicals (biologically derived drugs)
I take for my seronegative spondyloarthropathy, which increase
the risk of tumour because of their immunosuppressant nature.
Or perhaps it’s because of family history; my brother had a
melanoma. Or perhaps because I lived in west Africa as a baby
and toddler in the days before sun cream (but also in the days
when we had an ozone layer). Or maybe because I have that
pasty Scottish tartan skin which my dermatologist informs me
is Fitzpatrick type II. Or maybe a combination of all these
factors.
Finally, I had an appointment with the oncologist, who delivered
his monologue. Did I wish to go back on the biologicals that
everyone seemed to see as the cause of my melanoma? I wasn’t
sure. My understanding is that melanoma at this stage is sneaky
and aggressive and resistant to the usual chemotherapy channels
available for other cancers. Treatment is usually adjuvant
therapy in the form of interferon or clinical trials (such as
bevacizumab). The oncologist concluded that, because I have
arthritis and despite the rather disturbing fact that every other
patient with stage IIIa melanoma is offered it, I should not be
offered adjuvant therapy. He thought interferon would aggravate
the arthritis as it stimulates the immune system, and I would
not be eligible for the bevacizumab trial because of the arthritis.
Did he ask me for my opinion? No, he discharged me and
abandonedme tomy fate. I left, not understanding the likelihood
of recurrence or my chance of survival. I found the door
effectively closed in my face with the same recurring thought:
melanoma kills, arthritis does not.
To summarise the findings of my mole, my vocabulary now
included terms such as superficial spreadingmelanoma, sentinel
node, Breslow thickness, axillary clearance, lymphoedema,
micrometastases, and adjuvant therapy, but I still didn’t really
understand the process of recurrence and survival rates. Not
everyone with recurrence dies, right? And you can’t die if you
have no recurrence (excluding other causes like being hit by a
bus), so why did these figures not add up? The oncologist had
discharged me, which, to me, rather suggested that I was not
worth saving.
I didn’t actively seek a second opinion. I merely emailed my
rheumatologist to update him. This was normal as my care was
confusingly spread over three hospitals. The rheumatologist
emailed back immediately saying he thought that I shouldn’t
automatically be excluded from further treatment because of
my arthritis if this is what would normally happen. He then
(bless him) referred me to the oncologists at his hospital.
Weeks later, I faced a new oncologist. She disagreed with the
previous oncologists and enrolled me in the bevacizumab trial.
This is really confusing. Two centres run identical trials, yet I
am eligible for one and not the other? The cynic in me wonders
if one of these centres is skewing its results. This oncologist
didn’t dodge my questions but agreed with me that I needed to
know the facts so that I could make informed decisions. My
feeling was that everybody was expecting the cancer to recur
but nobody was saying it. Yes, she said, that is exactly what
they were all thinking.With all the other factors (arthritis, family
history) thrown in and a “significant chance of recurrence,” she
gave me a low five year survival probability (50%).
I haven’t taken my biologicals for one year now but must decide
if I wish to restart them. My rheumatologist informs me that
there is “a small but measurable risk” in terms of melanoma. I
cannot ignore the fact that I have chronic arthritis and must
balance the quality of my life with the risk the biologicals pose.
There may be no issue anyway as I may already be cured. I
don’t know. The excellent team who monitor me so closely
don’t know. But, I have every confidence that this team will
“sherpa” me to the top of the five year mountain, where I will
triumphantly plant my very own flag.
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A doctor’s perspective
When Penny first showed me the mole on her abdomen, I experienced that sinking feeling that a dermatologist feels when they are fairly
sure that they are staring at a new presentation of a melanoma. I had been suspicious after taking the history: a longstanding mole that had
changed shape and colour in a patient with very pale skin. Penny had been born in England but had spent much of her youth in sunny
countries. When I asked her if she had ever worn any sun protection as a child, she laughed and said, “We wore nothing.” Penny’s brother
had already been diagnosed with a melanoma. In addition, because of her seronegative spondyloarthritis, she had previously taken several
immunosuppressive drugs, some of which are believed to increase the risk of developing cancer.
At this point it is difficult to know whether to be completely open and voice your suspicions or wait until you have histological confirmation.
This is where I try to “feel” what the patient wants to know at this stage. I told Penny that the mole needed to be removed and offered to
excise it at the end of the clinic. As she agreed straightaway, there was no need to heighten her anxiety by saying that it needed to be
removed urgently. Neither of us talked about “melanoma.” I removed the mole on her abdomen, giving it a small margin of surrounding
normal skin. I noted that she had several other unusual looking moles and wondered if she had the dysplastic naevus syndrome, which
increases a person’s likelihood of developing melanoma.
The histology report was verified after 10 days and confirmed my clinical suspicion—a superficial spreading malignant melanoma with a
Breslow thickness of 1.8 mm. The histology results were reviewed at the local and regional skin multidisciplinary team meeting, and further
treatment and investigations were recommended.
I brought Penny back to the clinic and braced myself to give her news that I thought she would not be expecting. Do I just come out with the
words “I am sorry but it is skin cancer” or do I work up to it slowly, firing “shots across the bow” as I was taught in my National Communication
Course. After one consultation, how can you gauge how best a patient will take bad news?
I always break bad news in the clinics with our skin cancer nurse specialist present, as support for the patient. My previous consultation with
Penny suggested that she would rather be told any bad news straight out—I hoped I had judged right.
When I explained the diagnosis to her, she looked almost relieved and said she had suspected that this would be the case. I explained that
further surgery would be required to remove some more skin from around the scar, but that we would also recommend her having a sentinel
lymph node biopsy from the draining lymph node basin. This staging investigation can be offered to patients who have had a melanoma
removed with a Breslow thickness over 1 mm. I dictated a referral to the plastic surgeons who would perform the surgery at the regional
skin cancer centre, and arranged to see Penny again after her surgery so that I could continue her skin surveillance and arrange any further
investigations. I gave Penny the contact details of our cancer nurse specialist, who was also named as her key worker—the person to contact
if she had any worries, fears, or delays in appointments.
I asked Penny if she had any further questions. Very rarely, in all the years that I have been giving bad news regarding skin cancer, has
anyone asked me “How long have I got?”
I was relieved when Penny smiled again and said she had no more questions and that we would meet up again after her surgery.
Penny Thomson
Resources for patients and clinicians
Macmillan Cancer Support (Access link here)—UK charity providing information on malignant melanoma, including how it is diagnosed,
possible treatments and side effects, and how to get further support
Cancer Research UK (Access link here)—UK charity providing information about melanoma, including survival rates and prognosis
British Association of Dermatologists (Access link here)—Professional organisation providing information and guidelines on “prevention,
diagnosis, referral and management” for melanoma
Goldstein BG, Goldstein AO. Diagnosis and management of malignant melanoma. American Family Physician 2001;63:1359-69 (www.
aafp.org/afp/2001/0401/p1359.html)—Informative article in a peer reviewed journal
SkinCancer Net (www.skincarephysicians.com/skincancernet/)—US website from the American Academy of Dermatology. Provides
information on melanoma, including staging (/staging.html) and recurrence (/melanoma_returns.html)
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e2319 doi: 10.1136/bmj.e2319 (Published 11 April 2012) Page 3 of 2
PRACTICE
